Newport Medical Instruments Inc. has been acquired by Covidien plc
January 2012 — Newport Medical Instruments, Inc. (Newport), a manufacturer of ventilators for the portable, home care and critical care markets, has been acquired by Covidien plc. for US$108 million.
Newport is a physician-led company, focused on the design and manufacture of dependable ventilators that are affordable for caregivers worldwide.
Covidien plc. is a leading global provider of healthcare products and recognized innovator in patient monitoring and respiratory care devices. Covidien creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence.
Our role in the transaction
Oaklins' team in Los Angeles was engaged by the shareholders of Newport to pursue a sale of the business.
Talk to the deal team
Adam Abramowitz
Oaklins Intrepid
Eduard Bagdasarian
Oaklins Intrepid
Steven Davis
Oaklins Intrepid
Related deals
Life & Mobility has attracted investor Bolster Investment Partners
Life & Mobility, a leading developer and manufacturer of premium mobility and rehabilitation solutions, has welcomed Bolster Investment Partners as a new shareholder. The partnership provides Life & Mobility with a strong long-term partner to support the company’s next phase of growth, with a continued focus on product innovation, strengthening its leading market position and further international expansion. The company’s mission remains to enhance the mobility, independence and quality of life of end users through innovative, sustainable and circular mobility solutions designed for multiple life cycles.
Learn moreAsana Gruppe has sold selected outpatient service areas to Luzerner Kantonsspital
Luzerner Kantonsspital (LUKS) has acquired key parts of Asana Spital Menziken AG’s outpatient services from Asana Gruppe AG, including its ambulance service, primary care practice and ambulatory care center. The transaction supports the long-term continuity of local medical care in the Swiss Wynen and Seetal regions and ensures these services remain available close to patients’ homes.
Learn moreLaboratoires Herbolistique has received a majority investment from Yotta Capital Partners and co-investors
Laboratoires Herbolistique has received a majority investment from Yotta Capital Partners alongside co-investors Ouest Croissance, Sodero and CE IDF, with Bpifrance, Océans Participations and the management team reinvesting.
Learn more